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The intent of this review is to focus on recent advances
in the understanding of the factors responsible for the pro-
gressive pathologic features of diabetic kidney disease, with
special attention to various growth factors and cytokines
that appear to be important in this process. In addition,
emphasis is centered on relatively early stages of the dis-
ease, because animal models have been most helpful to date
inunderstandingthisstageofthediseaseprocess.Although
tubulointerstitial changes are of critical importance in the
progressionofdiabeticnephropathy,especiallyintheevolu-
tion to end-stage renal disease, there is a general consensus
thatglomerularpathologyoccursﬁrst.Therefore,attention
is limited to factors that may be important in the devel-
opment of early diabetic glomerulopathy, including trans-
forming growth factor-beta (TGF-β), insulin-like growth
factor (IGF)-I, vascular endothelial growth factor (VEGF)-
A, and connective tissue growth factor (CTGF).
Keywords Diabetes Mellitus; Diabetic Nephropathy; Growth
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INTRODUCTION
Thepathogenesisofdiabeticnephropathyremainsoneofthe
most important enigmas in clinical nephrology. Diabetes is the
most common cause of renal failure in the United States and in
manydevelopedcountries,accountingformorethan43%ofall
patients reaching end-stage renal disease in the United States
between 1996 and 2000 (U.S. Renal Data Systems, 2002).
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Moreover,theincidenceofbothdiabetesanddiabeticnephropa-
thy has increased at near epidemic proportions during the last
decade(U.S.RenalDataSystems,2002).Althoughseveralclin-
ical interventions, including tight glycemic control, treatment
of hypertension and use of angiotensin-converting enzyme in-
hibitors and angiotensin receptor blockers, have been shown
to retard the progression of nephropathy in many diabetic pa-
tients, the numbers of patients progressing to end-stage renal
disease continues to increase yearly (U.S. Renal Data Systems,
2002). Thus, an improved understanding of the pathogenesis
of this critical complication is being sought by many investi-
gators around the world. The intent of this review is to focus
on recent advances in our understanding of the factors respon-
sible for the progressive pathologic features of diabetic kidney
disease, with special attention to various growth factors and
cytokines that appear to be important in this process. In addi-
tion, emphasis will be centered on relatively early stages of the
disease, because animal models have been most helpful to date
in understanding this stage of the disease process. Although
tubulointerstitial changes are of critical importance in the pro-
gression of diabetic nephropathy, especially in the evolution
to end-stage renal disease, there is a general consensus that
glomerular pathology occurs ﬁrst. Therefore, we will limit our
attentiontofactorsthatmaybeimportantinthedevelopmentof
early diabetic glomerulopathy, including transforming growth
factor-beta (TGF-β), insulin-like growth factor (IGF)-I, vascu-
lar endothelial growth factor (VEGF)-A, and connective tissue
growth factor (CTGF).
PATHOLOGY OF EARLY DIABETIC
GLOMERULOPATHY
Over the past 20 years, it has become clear that relatively
subtle morphological changes in the renal glomerulus occur
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quite early during the evolution of diabetic nephropathy and
presage development of the diffuse and nodular sclerosis that
are the characteristic lesions of overt diabetic glomerulopathy.
Many studies have emphasized the widening of the glomerular
basement membrane and expansion of the extracellular ma-
trix area in the mesangium as the sites of important early
changes. Mauer and colleagues showed that expansion of the
extracellular mesangial matrix best predicted ultimate pro-
gression to frank glomerular sclerosis (Mauer et al., 1984).
Logically, therefore, many investigators have emphasized fac-
tors that contribute to increased mesangial matrix accumula-
tion in their research into the pathogenesis of early diabetic
nephropathy.
More recently, it has become clear that the glomerular ep-
ithelial cell, or podocyte, is also damaged early in diabetes
(Meyeretal.,1999;Pagtalunanetal.,1997;Hoshietal.,2002b).
Podocytesarehighlycomplexcellscomprisedinpartofarboriz-
ing processes terminating in interdigitating foot processes that
enveloptheglomerularcapillariesandwhosemajorfunctionap-
pears to be to create the ﬁltration barrier that keeps circulating
macromolecules within the circulation and out of the glomeru-
lar ﬁltrate. Several studies of human diabetic glomeruli have
stronglysuggestedthatdamagetopodocytesmaybejustasim-
portant,ifnotmoreso,thanthechangesthatoccurinmesangial
cells and in the extracellular glomerular mesangium. For ex-
ample, Meyer and colleagues have shown that loss of glomeru-
lar podocytes is an early event in diabetic nephropathy and
is highly predictive of both progressive glomerular injury and
long-term albumin excretion in diabetic patients (Meyer et al.,
1999; Pagtalunan et al., 1997). Because the mature podocyte
has limited capacity to divide and to be replaced after injury,
thislossfromglomerulicausedbydiabetesmayeventuallylead
to albuminuria, glomerular scarring (glomerulosclerosis), and,
ultimately, end-stage renal disease.
EXPERIMENTAL MODELS OF DIABETIC
NEPHROPATHY
A number of animal models of diabetic kidney disease have
been investigated over the past several decades. Although sev-
eral of these models recapitulate many or most of the early
pathologic features of diabetic nephropathy just described,
none of them fully reproduce the disease process found in hu-
mans. The features lacking from all currently described mod-
els are profound albuminuria (10- to 100-fold normal values)
and diffuse or nodular glomerular sclerosis, followed by pro-
gressive decline in glomerular ﬁltration rate to end-stage re-
nal disease. Although some models appear to have one or an-
other of these features, no reported model recapitulates this
program. Thus, until such a model exists, conclusions about
causalandpathogenicfactorsarenecessarilyprovisional.How-
ever, many animal models do reasonably faithfully repeat the
early changes of diabetic nephropathy: glomerular hyperﬁltra-
tion (i.e., increased glomerular ﬁltration rate), glomerular hy-
pertrophy,widenedglomerularbasementmembrane,mesangial
matrix expansion, and podocyte damage or loss. Therefore, it
appears that the current models should be able to shed some
light on the early changes of diabetic nephropathy in humans.
Parenthetically, because mouse models have recently be-
come more frequently utilized in the study of diabetes and
its complications, it has become clear that serum creatinine
measurements, performed by picric acid methods, do not reli-
ably predict glomerular ﬁltration rate in mice when compared
to inulin clearance or other reliable methods (Animal Mod-
els of Diabetic Complications Consortium, unpublished data;
www.amdcc.org). This appears to be due to competing chro-
magens in mouse serum that artifactually inﬂate the measured
creatinine level severalfold in mice with normal renal function
(Animal Models of Diabetic Complications Consortium, un-
published data). Accurate measurements of serum creatinine
that give creatinine clearances that closely approximate inulin
clearances can be obtained with high-performance liquid chro-
matography (HPLC) measurements of serum creatinine. Thus,
all reports of serum creatinine or creatinine clearances using
the picric acid (Jaffe) method on serum samples need to be
reinterpreted in light of the preceding discussion.
TROPHIC FACTORS AND CYTOKINES
IN EARLY DIABETIC RENAL DISEASE
Many factors have been implicated in the initiation of these
earlyglomerularchangesindiabetes.Inthisshortreview,itwill
be impossible to give justice to the scope of the research that
has been published in this area. Rather, this survey will focus
on those factors that, in the author’s opinion, are most clearly
pathogenically associated with diabetic kidney disease, with
some attention as well to newer and provocative reports. The
effects of these factors on mesangial cell and, when possible,
podocyte responses will be emphasized. Although many of the
signaling events have been initially elucidated via cell-culture
experiments, only those pathways with substantial validation
from experimental animal models of diabetes will be empha-
sized.Ageneraloverviewofsomeoftheseprocessesisoutlined
in Figure 1.
GLUCOSE, GLUCOSE TRANSPORTERS
AND ADVANCED GLYCATION
END PRODUCTS (AGEs)
Althoughnotusuallyclassiﬁedassuch,itiswisetorecallthat
glucose is the ultimate trophic factor in diabetic nephropathy.TROPHIC FACTORS AND CYTOKINES 227
FIGURE 1
Growth factor effects in the diabetic glomerulus. High extracellular glucose is transported into both mesangial cells and
podocytes by facilitative glucose transporters and engenders the elaboration of different growth factors from each of these cells.
Several of these are represented in this ﬁgure with schematic representation of signaling and interactions. VEGF-A = vascular
endothelial growth factor-A. TGF-β1 = transforming growth factor-beta 1. CTGF = connective tissue growth factor.
GLUT1/4 = facilitative glucose transporters 1 and 4. α5β1 = α5β1 integrin.
Similar to other factors, it interacts with a speciﬁc “receptor,”
in this case a facilitative glucose transporter, in order to en-
ter a cell and have intracellular effects. Indeed, many cells are
relatively protected from the effects of glucose because they
have limited numbers of such transporters or reduce the plasma
membraneexpressionofsuchtransportersinthepresenceofel-
evated levels of extracellular glucose (Duelli et al., 2000; Hahn
et al., 1998; Kaiser et al., 1993). This protective response ap-
pears to be lacking in renal glomerular mesangial cells in cul-
ture and in vivo, which, in fact, augment their levels of glucose
transporterswhenextracellularglucoselevelsrise(Heiligetal.,
1997b; D’Agord et al., 2001; Liu et al., 1999). Similar changes
have been reported in retinal endothelial cells, another target
tissueforcomplicationsindiabetes(Kumagaietal.,1996).The
effect of high glucose levels on podocyte glucose transporters
has not yet been reported. Many of the effects of elevated ex-
tracellular glucose can be reproduced simply by increasing the
number of glucose transporters in cells and thereby enhancing
glucose uptake and metabolic ﬂux (Heilig et al., 1995, 1997b;
Henryetal.,1999;Weigertetal.,2003).Conversely,manyofthe
effects of elevated extracellular glucose can be prevented sim-
ply by reducing the number of plasma membrane transporters
(Heilig et al., 2001).
The major glucose transporter in mesangial cells is the
so-called constitutive transporter, GLUT1, although GLUT4,
the insulin-responsive glucose transporter, is also expressed in
these cells in culture and in vivo (Brosius et al., 1992). GLUT1
is the transporter that is expressed at increased levels in mesan-
gial cells grown in high glucose (Heilig et al., 1997b) and in
glomeruli in experimental animals (Brosius et al., unpublished
observation). Although the glucose transporters in podocytes
have not been well characterized, both GLUT1 and GLUT4
appear to be expressed (Brosius et al., 1992; Coward et al.,
2002; Brosius et al., unpublished observation).228 F. C. BROSIUS, III
Glucose is the progenitor of another class of trophic factors
that are often not regarded as such: AGEs. These adducts also
have important signaling effects on glomerular cells. AGEs are
generated through a series of nonenzymatic reactions between
glucose and proteins or lipids and accumulate in diabetic pa-
tientsatamuchhigherratethantheydoinnormals.Highlevels
of AGEs have been implicated in the development of every dia-
beticcomplication.Thereisstrongevidencethattheseendprod-
ucts contribute to the development of diabetic nephropathy and
that inhibiting their formation with agents such as aminoguani-
dine can markedly ameliorate nephropathy in experimental an-
imals (Vlassara and Palace, 2002; Abdel-Rahman and Bolton,
2002), though such trials have been less conclusive in human
diabetic patients (Abdel-Rahman and Bolton, 2002). Although
AGEs have extracellular effects, such as protein cross-linking,
that appear to promote the expansion of the glomerular mesan-
gial matrix and basement membrane in diabetic nephropathy,
they also affect glomerular cells in a manner similar to growth
factors and other ligands, by binding to a series of receptors
known as RAGEs (receptor for advanced glycation end prod-
ucts). Ligation of these receptors leads to the stimulation of
a number of cytokines, including TGF-β (see below), as well
as increased synthesis of extracellular matrix proteins. Thus,
AGEs may be one of the proximal “growth factors” in driv-
ing the cellular machinery of the glomerulus to overproduce
matrix proteins and engender other changes of diabetic kidney
disease.
AfullreviewoftheeffectsofAGEsandextracellularglucose
on diabetic glomeruli is beyond the scope of this article. The
remainingdiscussionwillfocusongrowthfactorsandcytokines
as conventionally deﬁned.
TGF-β
TGF-β hasprobablyreceivedmorerecentattentionthanany
other trophic factor, in both the initiation and progression of di-
abetic nephropathy. There are three members of the TGF-β
family expressed in mammalian cells, TGF-β1, TGF-β2, and
TGF-β3(ChengandGrande,2002).Actingthroughtwoplasma
membrane receptors, these peptide factors have myriad effects
on cell growth and development, cell cycle regulation, inﬂam-
mation and immune responses, extracellular matrix protein ac-
cumulation, and a number of other processes. These signals
are generally transduced by transcription factors of the SMAD
protein family. These factors lead to gene regulation events re-
sponsible for the proﬁbrotic and hypertrophic effects of TGF-β
that have been implicated in a number of progressive renal dis-
eases (Cheng and Grande, 2002; Flyvberg, 2000).
TGF-β1 and TGF-β1 receptors are expressed in glomeru-
lar cells, including mesangial cells and podocytes (MacKay
et al. 1989; Ziyadeh et al., 1994; Abbate et al., 2002; Schiffer
etal.,2001,2002).Elevatedextracellularglucoselevelsaswell
as exposure to glycosylated albumin lead to enhanced TGF-
β production as well as TGF-β signal transduction in cultured
mesangialcells(Ayoetal.,1990;Cohenetal.,1995).Similarly,
experimental diabetes increases glomerular TGF-β1 produc-
tion and signaling (D’Agord et al., 2001; Shankland and
Scholey,1994;SharmaandZiyadeh1994).Moreover,autocrine
stimulationofmesangialcellTGF-β1receptorsbyhighglucose
enhances extracellular matrix protein accumulation (Ziyadeh
et al., 1994) and is associated with renal hypertrophy in animal
models (Shankland and Scholey, 1994; Sharma and Ziyadeh,
1994). Finally, enhanced TGF-β induces GLUT1 expression in
mesangial cells (Inoki et al., 1999), leading to increased glu-
cose metabolic ﬂux and enhanced matrix production as noted
above. Thus, TGF-β action in glomerular mesangial cells leads
to changes that appear to be central to the development of dia-
betic nephropathy.
Recent reports indicate that cultured podocytes respond
somewhatdifferentlythandomesangialcellsintermsofTGF-β
signaling (Iglesias-de la Cruz et al., 2002). Elevated extracel-
lular glucose levels do not increase TGF-β1 mRNA or protein
in the podocyte, but elevated glucose did induce expression of
the ligand-binding TGF-β type II receptor, suggesting that en-
hanced TGF-β signaling may ensue (Iglesias-de la Cruz et al.,
2002). The role of TGF-β signaling in the podocyte is just be-
ginning to be elucidated. Whether such signaling is important
in the development of diabetic glomerular changes remains to
be determined.
Perhaps the most compelling data that implicate TGF-β
production and signaling in the pathogenesis of experimen-
tal diabetic nephropathy are studies by Ziyadeh and col-
leagues demonstrating the prevention or amelioration of dia-
betic nephropathy by administration of speciﬁc anti–TGF-β
antibodies. Reduction of TGF-β signaling by administration of
anti–TGF-β antibodiesstartingat8weeksofageindb/dbmice
(approximately 4 weeks after onset of diabetes) prevented the
increase in albuminuria and accumulation of mesangial matrix
proteinseeninmicetreatedwithanunrelatedantibody(Ziyadeh
etal.,2000).Morerecentstudiesbythesamegrouphaveshown
that glomerular basement membrane (GBM) thickening and
mesangial matrix expansion could be reversed by administra-
tion of these antibodies to db/db mice starting at 16 weeks of
age (Chen et al., 2003).
Even though TGF-β1 levels increase early in diabetic
nephropathy (Shankland and Scholey, 1994), it is not certain
at what time point in this progression that its effects are most
important. It is clear that certain features of diabetic nephropa-
thy can occur without a signiﬁcant increase in TGF-β levels,
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found that exposure to high glucose increases protein kinase
C (PKC) activity, PKCα levels, and ﬁbronectin synthesis in
cultured mesangial cells, despite a lack of change in TGF-β
levels. These recent data indicate that increased glucose uptake
andmetabolisminducePKC-dependentactivatorprotein(AP)-
1 activation that is sufﬁcient for enhanced ﬁbronectin produc-
tion, but not for increased TGF-β1 expression (Weigert et al.,
2003). Despite such data, TGF-β appears to be a critical factor
in the progression of diabetic nephropathy in experimental an-
imals. Whether it is critical in the earliest changes that set the
process in motion is somewhat less certain.
Finally, it should be mentioned that other members of the
TGF-β family may participate in the pathogenesis of dia-
beticnephropathy.However,therehavebeenfewinvestigations
regarding these factors. One of these, bone morphogenetic
factor-7 (BMP-7), has been found to decline in kidneys from
streptozotocin diabetic rats (Wang et al., 2001). There is evi-
dence that BMP-7 plays an antiﬁbrotic role in kidney proximal
tubules, and therefore decreased expression of this factor in di-
abetes may augment tubulointerstitial ﬁbrosis. Whether it has
effects on mesangial expansion or podocyte damage in early
diabetic nephropathy has not been established.
GROWTH HORMONE (GH) AND IGF-I
GH, IGF-I, and the GH/IGF-I axis have been implicated in
the development of diabetic complications for some time. Al-
though a number of studies support the role of these factors
in the development of diabetic nephropathy, there remains less
clear-cut evidence for their participation than for TGF-β.G H
levels vary between models but tend to be elevated in several
diabetic models (Flyvberg, 2000). GH induces expression of
IGF-I in many tissues, including kidney (Flyvberg, 2000). In
addition, renal levels of IGF-I are elevated in some (Flyvberg,
2000) but not all (Bach et al., 2000) reports of experimental
models of diabetes. Even in models with increased IGF-I lev-
els, there are increased levels of IGF-binding proteins (IGF-
BPs), some of which may counteract the signaling effects of
IGF-I. In addition, circulating IGF-I levels are depressed in di-
abetes (Thrailkill, 2000), so the changes in the GH/IGF-I axis
in diabetic kidneys are quite complex.
The effects of GH and IGF-I on glomerular cells are also
complex, although in general both promote glomerular hy-
pertrophy and accumulation of extracellular mesangial matrix
proteins (Baud et al., 1999). Most GH effects on glomeru-
lar hypertrophy appear to be IGF-I dependent, but at least in
some cases GH effects on glomerular sclerosis may be in-
dependent of IGF-I (Baud et al., 1999). In accord with this,
infusion of IGF-I appears to enhance renal hypertrophy in
diabetic rats without albuminuria, whereas GH-deﬁcient rats
appear to have blunted glomerular hypertrophy as well as al-
buminuria when compared to control rats (Gronbaek et al.).
In addition, IGF-I can also have direct effects on mesangial
matrix protein accumulation. For example, IGF-I treatment of
mesangial cells from nondiabetic NOD mice resulted in a de-
crease in metalloproteinase (MMP)-2 activity, whereas treat-
mentwithaneutralizingantibodyagainstIGF-Irestoredtheac-
tiveformofMMP-2(Lupiaetal.,1999).MMP-2isaproteinase
that is critical in degrading extracellular matrix proteins, so
IGF-I–induced inhibition of this metalloproteinase could lead
to enhanced accumulation of extracellular matrix in diabetic
glomeruli.
ResultsofstudieswiththeGHantagonist,somatostatin,and
its analogs are also supportive of the role IGF-I in augment-
ing diabetic nephropathy. Somatostatin inhibits GH and IGF-I
action through a decrease in GH secretion and/or IGF-I ex-
pression or through a direct blockade of glomerular cell pro-
liferation. Several groups have found that long-acting somato-
statin analogs retard the development of mesangial expansion
and albuminuria (Flyvberg, 2000). For example, a recent report
showed that PTR-3173, a novel somatostatin analogue that has
prolongedinhibitoryactionontheGH/IGF-Iaxis,counteracted
some of the changes in kidney weight, glomerular volume, al-
buminuria, and creatinine clearance seen in untreated diabetic
NOD mice (Landau et al., 2001). Another long-acting somato-
statin compound, octreotide, was tested on renal function fol-
lowing induction of streptozotocin-diabetic rats. Chronic ad-
ministration of octreotide for 7 days prevented the decrease
of effective renal vascular resistance, and the increases in ﬁl-
tration fraction and glomerular ﬁltration rate induced by dia-
betes. However, it only partly prevented the renal hypertrophy
due to diabetes (Bak et al., 2001). Finally, IGF-I can induce
GLUT1 expression in mesangial cells independent of the ef-
fects of extracellular glucose on GLUT1 levels (Heilig et al.,
1997b). Therefore, IGF-I may augment the injury due to in-
creased intracellular glucose in these cells. However, whether
IGF-I promotes this effect in vivo has not yet been determined.
In sum, these studies generally support the conclusion that
enhanced IGF-I signaling probably occurs in diabetic glomeru-
lar cells and that such signaling contributes to glomerular hy-
pertrophy and possibly to accumulation of extracellular matrix
proteins in early diabetic nephropathy. It seems unlikely that
IGF-I or GH plays a central role in the progression of dia-
betic nephropathy because many of these events can be aug-
mented by TGF-β independent of IGF-I. Moreover, TGF-β
expression and action do not appear to be critically dependent
on IGF-I signaling. Finally, somatostatin analogs, which have
additional effects that are not due to changes in the GH/IGF-
I axis, only partly inhibit the development of early diabetic
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VEGF-A
Recently, a number of studies have examined the role
of VEGF-A in promoting diabetic nephropathy. In part this
has been driven by the growing evidence that VEGF-A is a
pathogenic factor in the evolution of diabetic retinopathy. In
addition, it has recently become clear that VEGF-A has very
important renal glomerular effects. VEGF-A mRNA and pro-
tein are expressed by mesangial cells (Iglesias-de la Cruz et al.,
2002; Yamagishi et al., 2002) and podocytes (Hoshi et al.
2002b) in culture, but the most critical expression of VEGF-
A in vivo in the kidney appears to be in the podocyte. A very
recent report has shown that both over- and underexpression of
the VEGF-A gene in the podocyte lead to signiﬁcant glomeru-
lar abnormalities, including albuminuria and endotheliosis
(underexpression) or collapsing glomerulopathy (overexpres-
sion) (Eremina et al., 2003). VEGF-A mRNA expression is
induced in glomerular cells by high glucose or AGEs (Iglesias-
de la Cruz et al., 2002; Yamagishi et al., 2002; Hoshi et al.,
2002b) and is enhanced in renal cortex from obese diabetic
Zucker fa/fa rats when compared to lean, nondiabetic control
rats (Hoshi et al., 2002a).
In studies conceptually similar to those performed with
TGF-β antibodies, two groups investigated whether a neutral-
izing VEGF antibody would ameliorate changes of diabetic
nephropathy in experimental diabetes, either streptozotocin-
diabetic rat or db/db mouse models (de Vriese et al., 2001;
Flyvberg et al., 2002). The animals received the antibody for
6 to 8 weeks. In the VEGF antibody–treated animals, kidney
weight, glomerular hypertrophy, basement membrane thick-
ness,hyperﬁltration,andurinaryalbuminlevelswerealldimin-
ished compared to the diabetic groups receiving the irrelevant
immunoglobulin G (IgG) injections. VEGF antibody adminis-
tration tended to reduce expansion of total mesangial volume
seen in diabetic animals, but this was not statistically signiﬁ-
cant. In one study, the investigators also noted that the increase
in creatinine clearance (as an estimate of glomerular ﬁltration
rate) seen in the control diabetic animals was abolished by the
VEGF antibody treatment (Flyvberg et al., 2002). However,
serum creatinine levels were performed using the picric acid
(Jaffe) method and therefore these values and the creatinine
clearancesthatwerecalculatedusingthemaresuspect,asnoted
above. Thus, many but not all of the early features of diabetic
nephropathy were ameliorated by chronic inhibition of VEGF
in db/db mice.
Recent studies also suggest that elevated circulating VEGF
levels is not a common feature of early diabetic kidney disease
in humans, and in fact, those with early indications of progres-
sive kidney disease may have lower levels of VEGF than those
who have no markers of kidney disease (Shimada et al., 2002).
Although kidney and glomerular levels may differ from those
in the blood, these ﬁndings question the importance of VEGF
as a pathogenic factor. Finally and critically, in some studies in
nondiabetic humans and animals, infusion of neutralizing anti-
VEGF antibodies or soluble VEGF receptors is associated with
proteinuria(Sugimotoetal.,2003),suggestingthatreductionof
VEGFlevelscanleadtoglomerulardysfunctionandpathology.
Thus, it remains unclear whether VEGF plays a pathogenic or
protective role, or both, in glomeruli in diabetes. More deﬁni-
tive studies will be necessary before any ﬁrm conclusions can
be drawn. What is certain, however, is that VEGF-A plays a
critical role in maintaining glomerular integrity, so it will not
be surprising to ﬁnd that relatively subtle changes in VEGF-A
levels or signaling lead to glomerular abnormalities in diabetic
kidney disease.
CTGF
Duringthepastseveralyears,therehasbeengrowinginterest
in CTGF (also known as CCN2) as an inducer of early diabetic
nephropathy. It has been shown that this growth factor is in-
duced in glomeruli from db/db diabetic mice after 3.5 months
of diabetes (Riser et al., 2000) and in streptozotocin-diabetic
rats after 32 weeks (Twigg et al., 2002). CTGF protein is also
present in glomeruli of human patients with diabetic nephropa-
thy (Wahab et al., 2001). Exposure of cultured mesangial cells
to high glucose causes a twofold rise in CTGF protein lev-
els within 48 hours (Riser et al., 2000). At least under these
experimental conditions, CTGF appears to act downstream of
TGF-β (Riser et al., 2000; Wahab et al., 2001; Abdel-Wahab
et al., 2002). AGEs also stimulate CTGF expression in cul-
tured mesangial cells (Twigg et al., 2001, 2002). Treatment of
streptozotocin-diabetic rats with aminoguanidine, an inhibitor
ofAGEformation,reducedCTGFtonormallevels(Twiggetal.,
2002). Inhibition of CTGF expression in mesangial cells by
an antisense oligonucleotide approach or a chick anti-CTGF
neutralizing antibody resulted in a diminution of high glucose–
induced ﬁbronectin accumulation in cultured mesangial cells
(Wahab et al., 2001). Finally, it appears that both TGF-β and
CTGF act to induce ﬁbronectin accumulation, in part via in-
duction of α5β integrin, a ﬁbronectin receptor on mesangial
cells (Weston et al., 2003). In this study, virtually all of TGF-β
effects were eliminated by CTGF antisense oligonucleotides.
A recent report has shown that CTGF stimulates cultured
human mesangial cells to enter the G(1) phase from G(0), but
then to arrest. CTGF was shown to stimulate expression of
the cyclin-dependent kinase inhibitors (CDKIs) p15(INK4),
p21(Cip1), and p27(Kip1), which inactivate cyclins D and
E complexes, which could thereby inhibit cel-cycle progres-
sion. These ﬁndings imply that elevated CTGF levels may ac-
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diabetic nephropathy. Moreover, in this report, blockade of
CTGFsignalinginterruptedTGF-β–inducedhypertrophy,sug-
gesting that CTGF acts downstream of TGF-β in this system
as well (Abdel-Wahab et al., 2002).
These recent data suggest that CTGF may serve as an im-
portantmediatorofTGF-β–inducedglomerularmesangialma-
trix accumulation in diabetic animals. Whether CTGF can be
induced independently of TGF-β or whether it is important
in earlier changes of diabetic nephropathy remain to be eluci-
dated. Nonetheless, its effects may be more speciﬁc than those
ofTGF-β andtherebypotentiallymoreamenabletotherapeutic
intervention.
OTHER CYTOKINES OR GROWTH FACTORS
Several studies have implicated platelet-derived growth fac-
tor (PDGF) and epidermal growth factor (EGF) in promoting
diabetic nephropathy. PDGF mRNA levels are reported to be
increased in streptozotocin-diabetic rats after 6 months of di-
abetes (Kelly et al., 2001). However, there is little evidence
pointing to a direct role for PDGF in the evolution of early di-
abetic kidney disease. In fact, there appears to be no aggravat-
ing role of PDGF in diabetic condition because treatment with
PDGFfailedtoleadtoanydevelopmentofprogressivediabetic
nephropathy in Goto Kakizaki diabetic rats, a genetic model of
nonobesetype2diabetesmellitusinwhichprogressivediabetic
kidney disease does not develop (Riley et al., 1999).
Similarly,severalreportsofincreasedEGFexpressionraised
thepossibilitythatthisgrowthfactoralsoparticipatedinthede-
velopmentofdiabeticnephropathy.Indeed,thekidneyisoneof
themajorsitesofEGFproduction,thoughitislargelyproduced
in cells in the distal nephron and unlikely to activate receptors
that are known to exist in mesangial cells (Harris et al., 1988).
As yet, there are no reports of EGF or EGF receptor expression
in podocytes. Urinary EGF levels rise within the ﬁrst week of
diabetes but renal levels do not appear to be increased (Gilbert
et al., 2002). There are no direct studies that have investigated
the role of EGF signaling in promotion of the cardinal events
of early diabetic nephropathy.
SUMMARY
The changes of early diabetic nephropathy set the stage
for progressive glomerulosclerosis and tubulointerstitial ﬁbro-
sis and atrophy that characterize the failing diabetic kidney. A
numberoftrophicfactorsandcytokinesappeartopromotethese
earlychangesbyeffectsonbothmesangialcellsandpodocytes.
The precise nature of these nephropathy-promoting effects still
remain to be elucidated and the manner in which the various
factors interact to induce nephropathy has yet to be really stud-
ied. Nonetheless, these factors and cytokines, as well as the
signaling events they trigger in mesangial cells and podocytes,
are important potential targets for therapeutic efforts designed
to forestall progressive diabetic nephropathy. Successful treat-
mentofearlydiabeticnephropathywouldhaveprofoundeffects
on the well-being and life expectancies of millions of diabetic
patients.
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